This site is intended for healthcare professionals
News

Final SPECTRA phase II/III clinical trial efficacy data for SCB 2019 is published in The Lancet.- Clover Biopharmaceuticals.

Read time: 1 mins
Published:22nd Jan 2022
Clover Biopharmaceuticals announced that final efficacy data from SPECTRA, a global Phase II/III clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB 2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.

The paper, ‘Efficacy of the adjuvanted subunit protein Covid-19 vaccine, SCB 2019: a phase II and III multicentre, double-blind, randomised, placebo-controlled trial,’.

SCB 2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoints. The COVID-19 vaccine candidate also demonstrated 100% efficacy against severe COVID-19 and hospitalization caused by any strain of SARS-CoV-2 in SPECTRA. SCB 2019 (CpG 1018/Alum) showed a favorable safety profile with no significant differences observed in systemic adverse events or severe adverse events when compared to placebo.

See- "Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB 2019: a phase II and III multicentre, double-blind, randomised, placebo-controlled trial". Lulu Bravo et al. The Lancet January 20, 2022DOI:https://doi.org/10.1016/S0140-6736(22)00055-1

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.